CoChat

Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials

Open access
Dejgaard, Thomas F., von Scholten, Bernt J., Christiansen, Erik, Kreiner, Frederik F., Bardtrum, Lars, von Herrath, Matthias, Mathieu, Chantal, Madsbad, Sten, ADJUNCT ONE and ADJUNCT TWO Investigators · 2021 · Diabetes, Obesity and Metabolism
Cited by 48

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Aim: To evaluate 26 weeks of liraglutide treatment in type 1 diabetes (T1D) by subgroups in the ADJUNCT ONE and ADJUNCT TWO trials. Materials and Methods: ADJUNCT ONE and ADJUNCT TWO were randomized controlled phase 3 trials in 1398 and 835 participants with T1D treated with liraglutide (1.8, 1.2, or 0.6 mg) or placebo (adjuncts to insulin). This post hoc analysis evaluated treatment effects by subgroups: HbA1c (< or ≥8.5%), body mass index (BMI; < or ≥27 kg/m 2 ), and insulin regimen (basal bolus or continuous subcutaneous insulin infusion). Results: In both trials at week 26, reductions in HbA1c, body weight, and daily insulin dose did not differ significantly ( P > .05) by baseline HbA1c or BMI. Risk of clinically significant hypoglycaemia or hyperglycaemia with ketosis did not differ significantly ( P > .05) by baseline HbA1c, BMI, or insulin regimen. At week 26 in ADJUNCT ONE, these risks did not differ ( P > .05) between treatment groups. Placebo‐adjusted reductions in HbA1c, body weight, and insulin dose (−0.30%‐points, −5.0 kg, and −12%, respectively, with liraglutide 1.8 mg), were significant ( P < .05), greater than at week 52, and similar to those in ADJUNCT TWO (−0.35%, −4.8 kg, and −10%, respectively, with liraglutide 1.8 mg). Conclusions: In ADJUNCT ONE and ADJUNCT TWO, the efficacy and glycaemic safety of liraglutide did not depend on subgroups, leaving residual beta‐cell function as the only identified variable impacting the effect of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) in T1D. These findings support a role for GLP‐1 RAs as adjuncts to insulin in T1D, warranting further study.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.14532

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 48

Metadata

Authors
Dejgaard, T. F., von Scholten, B. J., Christiansen, E., Kreiner, F. F., Bardtrum, L., von Herrath, M., Mathieu, C., Madsbad, S., & ADJUNCT ONE and ADJUNCT TWO Investigators
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2021-09-28
Volume
23
Issue
12
Pages
2752-2762
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W3198786326
Cited by
48
References
19
FWCI
3.89
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.